Citigroup
SKYE icon

Citigroup’s Skye Bioscience SKYE Stock Holding History

Citigroup’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Buy
+2
New +$2 ﹤0.01% 5881
2025
Q4 		– Sell
-1
Closed -$4 – 6557
2025
Q3 		$4 Buy
+1
New +$4 ﹤0.01% 5998
2025
Q2 		– Sell
-13,985
Closed -$22.2K – 5945
2025
Q1 		$22.2K Sell
13,985
-1,277
-8% -$3.49K ﹤0.01% 5066
2024
Q4 		$43.2K Buy
15,262
+2,738
+22% +$11.4K ﹤0.01% 5123
2024
Q3 		$49K Buy
12,524
+8,676
+225% +$48.7K ﹤0.01% 5026
2024
Q2 		$30.8K Buy
+3,848
New +$45.7K ﹤0.01% 4852

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citigroup's SKYE Position: Q1 2026 in Review

Citigroup opened a new position in Skye Bioscience (SKYE) in Q1 2026: 2 shares worth $1. The stake represents ﹤0.01% of the portfolio and ranks #5881 among its holdings. This is a return to the name: Citigroup previously reported a position in SKYE as recently as Q3 2025.

Citigroup first reported a position in SKYE in Q2 2024 and has held it in 6 quarters since. The position peaked at $49K in Q3 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Citigroup held 2 shares of Skye Bioscience worth $1 as of Q1 2026.
  • Skye Bioscience was a new Citigroup position in Q1 2026.
  • Skye Bioscience made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5881 holding.
  • Citigroup first reported a position in Skye Bioscience in Q2 2024 and has held it in 6 quarters since.
  • Citigroup's Skye Bioscience position peaked at $49K in Q3 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.